Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders
Brain Communications · 30.10.2024 · 6 (6)
DOI: 10.1093/braincomms/fcae414 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Communications, online erschienen am 19.11.2024. Verfasst von Bárbara Fernandes Gomes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 43180…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Horizon 2020, Marie Skłodowska-Curie.
Abstract (Originalsprache)
Disease-specific fluid biomarkers are in demand for parkinsonian syndromes (PS). Corticotropin-releasing hormone (CRH) was proposed as a biomarker for Lewy body disease. As such, this project aimed to confirm CRH as a potential biomarker for different PS. CRH and misfolded α-synuclein (αSyn) were measured in CSF. The primary cohort included Lewy body disease patients (i.e. Parkinson’s disease or dementia with Lewy bodies, n = 77), atypical PS (n = 37) and non-parkinsonian neurodegenerative diseases (n = 164), as well as controls (n = 354). A replication cohort included Lewy body disease (n = 27), atypical PS (n = 58) and controls (n = 58). CRH was downregulated in αSyn positive Lewy body disease, αSyn positive controls and in all atypical PS compared with αSyn negative controls (P = 3.3e−05, P = 3.1e−10, P = 2.9e−03). CRH was also decreased in αSyn positive Lewy body disease compared with αSyn negative non-PS (P = 2e−03) and correlated with cognitive impairment and inflammation in αSyn positive Lewy body disease. We show that CRH is a promising biomarker for Lewy body disease and atypical PS and its association with inflammation and cognitive decline. Reductions in CRH in Lewy body disease and other PS suggest this decrease may relate to dopaminergic degeneration instead of αSyn pathology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 43180 Mölndal, Sweden.
- Department of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, 20213 Malmö, Sweden.
- Banner Alzheimer's Institute and University of Arizona, Phoenix, AZ 85006, USA.
- Banner Sun Health Research Institute, Sun City, AZ 85351, USA.
- Memory Clinic, Skåne University Hospital, 20502 Malmö, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 43139 Mölndal, Sweden.
ORCID-Profile: Bárbara Fernandes Gomes, Atul Kumar, Sara Hall, Ruben Smith, Henrik Zetterberg, Niklas Mattsson-Carlgren, Oskar Hansson
Förderung
- NIA NIH HHS
- Horizon 2020
- Marie Skłodowska-Curie
- European Research Council
- Alzheimer's Association
- GHR Foundation
- Swedish Research Council
- ERA PerMed
Zitieren
APA
Fernandes Gomes, B., Kumar, A., Ashton, N. J., Hall, S., Stomrud, E., Smith, R., Zetterberg, H., Blennow, K., Mattsson-Carlgren, N., & Hansson, O. (2024). Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders. Brain Communications, 6(6). https://doi.org/10.1093/braincomms/fcae414
Vancouver
Fernandes Gomes B, Kumar A, Ashton NJ, Hall S, Stomrud E, Smith R, et al. Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders. Brain Communications. 2024;6(6). doi:10.1093/braincomms/fcae414
BibTeX
@article{FernandesGomes2024,
author = {Fernandes Gomes, Bárbara and Kumar, Atul and Ashton, Nicholas J and Hall, Sara and Stomrud, Erik and Smith, Ruben and Zetterberg, Henrik and Blennow, Kaj and Mattsson-Carlgren, Niklas and Hansson, Oskar},
title = {Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders},
journal = {Brain Communications},
year = {2024},
volume = {6},
number = {6},
doi = {10.1093/braincomms/fcae414}
}
EUVIMED